1-(2,3-二氯苯基)哌啶 | 28581-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2,3-二氯苯基)哌啶
• 英文名称: 1-(2,3-dichlorophenyl)piperidine
• CAS: 28581-91-1
• 化学式: C₁₁H₁₃Cl₂N
• 分子量: 230.137
• InChiKey: ZSHGYUKUMWBPMH-UHFFFAOYSA-N

物化性质

• 沸点：
  335.4±32.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2,3-二氯苯基)哌啶 、 7-(4-溴丁氧基)-3,4-二氢-2(1H)-喹啉酮 生成 阿立哌唑
  参考文献：
  名称：

  [EN] CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
  [FR] FORMULATION D'ARIPIPRAZOLE INJECTABLE STERILE A LIBERATION CONTROLEE ET PROCEDE

  摘要：

  公开号：

  WO2005041937A3

文献信息

• Controlled release sterile injectable aripiprazole formulation and method
  申请人：Kostanski W. Janusz

  公开号：US20050148597A1

  公开（公告）日：2005-07-07

  A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.

  本发明提供了一种控释无菌冻干阿立哌唑制剂，该制剂由所需平均粒径的阿立哌唑及其载体组成，在与水混合和肌肉注射后，阿立哌唑可在至少约一周至约八周的时间内释放。此外，还提供了制备控释冻干阿立哌唑制剂的方法，以及使用上述制剂治疗精神分裂症的方法。
• AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS TACHYKININ ANTAGONISTS
  申请人：Pfizer Limited

  公开号：EP1023285A1

  公开（公告）日：2000-08-02
• CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1675573A2

  公开（公告）日：2006-07-05
• CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATON AND METHOD
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20170348308A1

  公开（公告）日：2017-12-07

  A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
• US7807680B2
  申请人：——

  公开号：US7807680B2

  公开（公告）日：2010-10-05